期刊
HUMAN IMMUNOLOGY
卷 78, 期 9, 页码 559-564出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.humimm.2017.06.002
关键词
Elafin; Secretory leukocyte protease inhibitor; Rheumatoid arthritis; Systemic sclerosis
类别
资金
- Poznan University of Medical Sciences [502-14-01127189-08576]
Alarm antiproteases, i.e. secretory leukocyte protease inhibitor ad elafin, are key mediators in innate immune response and integrate innate and adaptive immunity systems. The aim of the study was to assess clinical significance of serum levels of alarm antiproteases, elafin and secretory leukocyte protease inhibitor (SLPI) in patients with systemic sclerosis (SSc). Twenty-eight patients with SSc, 25 patients with rheumatoid arthritis (RA) and 22 healthy controls were recruited. Serum elafin and SLPI levels were examined using enzyme-linked immunosorbent assay (ELISA). The patients with SSc had significantly increased serum levels of SLPI in comparison with the RA patients and the healthy controls (p < 0.01), and the RA patients presented significantly higher serum levels of elafin in comparison with the controls (p = 0.003). In the SSc subgroup serum SLPI level negatively correlated with diffusing capacity of the lung for carbon monoxide (DLCO) (r = -0.41, p = 0.03) and total lung capacity (r = -0.42, p = 0.03). Both alarm antiproteases, elafin and SLPI could be potentially implicated in the pathogenesis of SSc and SLPI may be considered a candidate for serum biomarker of lung involvement in SSc. (C) 2017 Published by Elsevier Inc. on behalf of American Society for Histocompatibility and Immunogenetics.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据